MedTrace Logo

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2012-10-12

No results posted yet for this study

Summary

The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

0.5 mg ranibizumab

DRUG

3 mg PF-04523655

DRUG

1 mg PF-04523655

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Quark Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-11-30
Completion
2011-07-31

Countries

  • United States
  • Austria
  • Denmark
  • Hong Kong
  • India
  • Israel
  • Philippines
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00713518 on ClinicalTrials.gov